Treatment as Prevention¨

卑詩研究中心與華合作 續研發愛滋病治療

綜合報道 卑詩愛滋病/愛滋病毒卓越研究中心(BC Centre for Excellence in HIV/AIDS)與中國疾病控制與預防中心(Chinese Centre for Disease Control and Prevention),再次簽署協議,共同研究和改良愛滋病治療方法,中國疾控中心將繼續推廣使用由卑詩省研發的「治療如同預防」(Treatment as Prevention)的對抗愛滋病方法。 愛滋病卓越研究中心總監蒙塔納(Julio Montaner)透露,雙方正式簽署新一份諒解備忘錄,未來3年內,中國將會派出3個專家到卑詩省共同進行研究工作。 卑詩省與中國醫療機構的愛滋病研究合作關係早於2009年開始。直至2011年,中國疾控中心正式宣布,採用由卑詩省研發的「治療如同預防」愛滋病治療方法,成為全球首個採納這個方法作為全國對抗愛滋病政策的國家。 至2013年11月,中國疾控中心與卑詩省簽署首份諒解備忘錄,建立為期3年的愛滋病研究合作項目,中方每年派出專家到來本省學習及共同研究。

卑詩研究中心與華合作 續研發愛滋病治療 Read More »

It’s time for Toronto to step up: Let’s become a UNAIDS Fast-Track City

The past few years have been a rollercoaster for those of us most impacted by HIV. The use of pre-exposure prophylaxis (PrEP) by people who are HIV-negative has gone from being discredited and shamed to become one of the keystones of a renewed and revitalized push to “end the HIV epidemic”. The other life-changing piece

It’s time for Toronto to step up: Let’s become a UNAIDS Fast-Track City Read More »

PrEP can ‘significantly’ reduce HIV rates across populations, study says

(CNN) – HIV pre-exposure prophylaxis or PrEP, the use of drugs to prevent HIV infection, among men who have sex with men can significantly reduce new infections across an entire population of men, a new study finds. Based on introduction of the intervention, HIV infections diagnosed in men who have sex with men in the

PrEP can ‘significantly’ reduce HIV rates across populations, study says Read More »

AIDS Drug Assistance Programs Must Navigate Costs and Needs of People With HIV

The ADAP Advocacy Association hosted its annual conference in late September, and it covered many subject areas along this year’s official theme, “Mapping a New Course to Protect the Public Health Safety Net.” The AIDS Drug Assistance Program, which was first established by Congress to pay for Retrovir (zidovudine, AZT) in 1987, was then incorporated

AIDS Drug Assistance Programs Must Navigate Costs and Needs of People With HIV Read More »

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below